AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Pompe Disease

Recent research efforts aimed at curing Pompe Disease.

Last updated
Also available in
Français — Maladie de Pompe

Pompe Disease

Overview

Pompe disease is a rare inherited disorder caused by harmful changes in both copies of the GAA gene, leaving the body with too little acid alpha-glucosidase (GAA), an enzyme needed to break down glycogen inside lysosomes, the cell’s recycling compartments. Glycogen then accumulates, especially in heart, skeletal, and breathing muscles. Infantile-onset Pompe disease usually begins in the first year of life with severe weakness, feeding problems, enlarged heart muscle, and respiratory distress; without treatment, death from heart-and-lung failure commonly occurs within the first two years. Late-onset Pompe disease can begin from childhood through adulthood and more often causes slowly progressive limb-girdle and breathing-muscle weakness, sometimes leading to wheelchair use or respiratory failure. Pompe Disease GeneReviews

The present standard of care is lifelong intravenous enzyme-replacement therapy (ERT), which supplies manufactured GAA, plus respiratory, cardiac, nutrition, physical-therapy, and immunologic care. In the United States, alglucosidase alfa is used across disease forms; avalglucosidase alfa is an option for people with late-onset disease older than one year; and cipaglucosidase alfa plus the oral enzyme stabilizer miglustat is approved for certain adults with late-onset disease who are not improving on prior ERT. ERT has substantially improved survival in infantile-onset disease, particularly when begun early, but it does not correct the patient’s DNA and is not a cure. Pompe Disease GeneReviews FDA Pombiliti trial snapshot

Scope of Recent Research (2020–present)

Research since 2020 has become notably more active and diversified: the central goal is to replace or restore GAA in hard-to-reach tissues, particularly skeletal muscle, diaphragm, heart, and nervous system, while avoiding harmful immune responses. The field has progressed from animal proof-of-concept work to several early human gene-therapy studies, including published results in infantile-onset disease and active trials in late-onset disease. However, no approach has yet shown durable, comprehensive correction across tissues in enough people and over enough time to establish a cure. AAV9 gene therapy in infantile-onset Pompe disease FORTIS trial record

Major Breakthroughs and Emerging Therapies

The leading curative strategy is in vivo gene replacement: delivering a working GAA gene using an adeno-associated virus (AAV), a modified viral carrier that generally does not cause disease. In a 2025 report, four infants with infantile-onset Pompe disease received one intravenous dose of AAV9-GAA therapy, called GC301. One participant withdrew and later died, but the other three showed improved cardiac outcomes and motor function during 52 weeks of follow-up; anti-GAA antibodies were not detected during that period. This was an important first clinical demonstration that systemic gene delivery can produce GAA and potentially reduce dependence on frequent ERT, but the study was very small and uncontrolled. AAV9 gene therapy in infantile-onset Pompe disease

A 2026 follow-up study examined GC301 in six older children with infantile-onset Pompe disease who had already received prolonged ERT. After a single AAV9-GAA infusion and ERT discontinuation, all six remained free of chronic ventilation over one year, although one temporarily required ventilatory support during pneumonia. The study reported no further improvement in lung function or cardiac structure, while biopsies from three children showed increased GAA activity and reduced glycogen accumulation. These findings are encouraging but preliminary: the cohort was small, one child withdrew early, and longer observation is essential because AAV gene therapy may lose effectiveness or reveal delayed safety issues. GC301 after ERT discontinuation

For adults with late-onset Pompe disease, Astellas’s AT845, also called zocaglusagene nuzaparvovec, uses an AAV8 vector designed to drive ongoing GAA production in muscle. The phase 1/2 FORTIS study remains active but is no longer recruiting. Astellas reported at its 2026 update that five of six participants with at least one year of follow-up had remained off ERT for one to more than 3.5 years; these company-reported data have not yet been published as a peer-reviewed clinical paper and should therefore be interpreted cautiously. FORTIS trial record Astellas 2026 FORTIS update

Researchers are also pursuing approaches that could address limitations of direct AAV gene replacement. Hematopoietic stem-cell gene therapy collects a person’s blood-forming stem cells, adds a functional GAA gene with a lentiviral vector outside the body, and returns the cells after conditioning treatment. In Pompe mouse models, this approach improved muscle and cardiac abnormalities in 2020, and a 2024 study using an engineered GAA uptake tag reported correction of both muscle and neurologic disease features, with integration-site and single-cell analyses supporting preclinical safety evaluation. Lentiviral stem-cell gene therapy in mice Preclinical lentiviral HSPC therapy

Gene editing aims to repair an individual’s disease-causing DNA variant rather than add another copy of the gene. In 2024, adenine base editing corrected three common nonsense variants in patient-derived infantile-onset Pompe fibroblasts. Edited cells recovered GAA activity into the normal range in the reported experiments and showed reduced lysosomal burden, but this remains laboratory-stage work; safe delivery of editing machinery to enough heart, skeletal-muscle, and nerve cells remains a major obstacle. Base editing in patient-derived Pompe cells

Clinical Trials and Experimental Approaches

The most consequential current clinical programs are AAV-based gene therapies. GC301 has produced early published results in infantile-onset disease through investigator-led Chinese studies, including a phase 1 trial in treatment-naive infants and a later study in ERT-experienced children. AT845 is in the phase 1/2 FORTIS trial for adults with late-onset Pompe disease, sponsored by Astellas Gene Therapies. AskBio, a Bayer subsidiary, began dosing the first participant in its phase 1/2 PROGRESS-GT LOPD trial of AB-1009 in May 2026; the single-arm, dose-escalation study is planned to enroll approximately 12 adults in the United States. GC301 infant trial registry FORTIS trial record AskBio AB-1009 trial announcement

A distinct experimental approach tries to lower glycogen production rather than replace GAA. Aro Biotherapeutics’ ABX1100 is a muscle-targeted small interfering RNA (siRNA) designed to reduce GYS1, the gene that encodes muscle glycogen synthase. Its early phase 1 study, which included healthy volunteers and people with late-onset Pompe disease, was listed as completed with 46 participants in 2026. Because reducing glycogen production does not repair the underlying GAA defect, this strategy is better viewed as a possible disease-modifying complement or alternative to ERT than as a stand-alone genetic cure. ABX1100 phase 1 trial record

Methodologies and Scientific Approaches

Pompe researchers use patient fibroblasts, induced pluripotent stem-cell systems, and Gaa-deficient mice and rats to test whether candidate treatments restore GAA activity, clear glycogen, improve muscle force, normalize heart structure, and preserve breathing. A 2025 rat study found that neonatal systemic AAV9-GAA treatment produced sustained improvements in cardiac and respiratory measures and reduced glycogen in heart, diaphragm, skeletal muscle, and spinal cord, illustrating why animal studies increasingly assess both muscle and nervous-system outcomes. Neonatal AAV-GAA therapy in Pompe rats

Human studies combine biological and functional measurements. These include GAA activity, glycogen-related markers such as urinary glucose tetrasaccharide (Hex4), anti-GAA and anti-AAV antibody testing, muscle biopsy, magnetic-resonance imaging, echocardiography, lung function, six-minute walk distance, and motor-development assessments. Such measures are necessary because a treatment may improve an enzyme or biopsy result without producing a meaningful improvement in breathing, mobility, or independence. Pompe Disease GeneReviews

Leading Institutions and Funding

Clinical translation is being driven by the Seventh Medical Center of the PLA General Hospital and GeneCradle in China through the GC301 studies; Astellas Gene Therapies through AT845; and AskBio/Bayer through AB-1009. The 2025 GC301 clinical report states that the work was funded by the National Natural Science Foundation of China and National High Level Hospital Clinical Research Funding. Astellas reported AT845 as a $73 million intangible asset in its March 2026 financial materials, an accounting figure that indicates substantial corporate investment but does not represent the total amount spent on the program. AAV9 gene therapy in infantile-onset Pompe disease Astellas 2026 FORTIS update

Important preclinical work has also come from collaborations involving University College London, McGill University’s Lady Davis Institute, Boston Children’s Hospital, Hannover Medical School, and other academic centers studying lentiviral stem-cell approaches. U.S. National Institutes of Health support is reflected in grants cited by recent AAV-GAA animal studies, while the growing number of academic-industry partnerships is helping move vector design, manufacturing, immune management, and clinical outcome measurement toward human testing. Preclinical lentiviral HSPC therapy Neonatal AAV-GAA therapy in Pompe rats

Strengths, Limitations, and Challenges

The greatest strength of gene replacement is its potential to change treatment from biweekly infusions to a one-time intervention that produces GAA continuously. Early GC301 and AT845 results suggest that this goal may be biologically achievable in at least some patients. AAV9 is particularly attractive for infantile-onset disease because it can reach heart and skeletal muscle, while AAV8 and muscle-directed expression strategies may be useful in adults with late-onset disease. AAV9 gene therapy in infantile-onset Pompe disease Astellas 2026 FORTIS update

The limitations are substantial. Existing trials are small, mostly open-label, and too short to demonstrate lifelong benefit. Pre-existing immunity to AAV can exclude people from treatment, and immune reactions may limit the dose or durability of gene expression. Muscle and especially the central nervous system remain difficult to treat completely, while AAV re-dosing is challenging because treatment induces antibodies against the viral carrier. Stem-cell gene therapy may offer broader, more durable enzyme delivery but requires chemotherapy-like conditioning and carries theoretical risks from integrating viral vectors. Base editing could be a true mutation-level cure for some people, but it is variant-specific and has not yet been proven in humans with Pompe disease. Base editing in patient-derived Pompe cells Preclinical lentiviral HSPC therapy

Outlook and Future Directions

As of October 27, 2026, Pompe disease does not have an established cure, but the field has moved meaningfully closer to durable treatment than it was in 2020. The next milestones to watch are multi-year outcomes from GC301-treated children, peer-reviewed full results from the AT845 FORTIS study, initial safety and enzyme-expression data from AB-1009, and evidence that next-generation vectors or stem-cell platforms can correct respiratory and neurologic disease as well as heart and skeletal-muscle disease. A convincing cure will require sustained clinical benefit, acceptable safety, durable correction across affected tissues, and practical access for both infants and adults. GC301 after ERT discontinuation FORTIS trial record AskBio AB-1009 trial announcement

References

Don't see your disease? Request a report